Also known as venus medtech hangzhou
Hangzhou Qiming Medical Devices Co., Ltd. is China's leading transcatheter heart valve medical device company. The company's independently developed product VenusA-Valve is the first transcatheter aortic valve replacement ("TAVR") product approved by the National Drug Administration ("NMPA") and commercially available in China. As a pioneer in China's transcatheter heart valve industry, the company has a first-mover advantage. The company’s mission is to become a global leader in the development and commercialization of transcatheter solutions for structural heart disease.
Browse more corporate investors and other institutional investors by location and type in the LPbacked limited-partner database.
Venus Medtech (Hangzhou) is a corporate investor based in Hangzhou, China, managing approximately $445M in assets.
Venus Medtech (Hangzhou) is headquartered in Hangzhou, China.
Venus Medtech (Hangzhou) manages approximately $445M in assets under management.
Venus Medtech (Hangzhou) was founded in 2009.
Venus Medtech (Hangzhou) focuses on Early Stage, Early Stage: Seed, Early Stage: Start-up, Expansion / Late Stage, Venture (General), Healthcare, Information Technology, Semiconductors.
Verified contact details, key decision-makers, and investment preferences for Venus Medtech (Hangzhou) are available on LPbacked. Create a free account to access them.